Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KOD 
Kodiak Sciences Inc (KOD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: KOD (4-star) is a STRONG-BUY. BUY since 131 days. Simulated Profits (297.10%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.71
1 Year Target Price $17.71
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 3 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1303.05% | Avg. Invested days 59 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 931.25M USD | Price to earnings Ratio - | 1Y Target Price 17.71 |
Price to earnings Ratio - | 1Y Target Price 17.71 | ||
Volume (30-day avg) 6 | Beta 2.71 | 52 Weeks Range 1.92 - 21.17 | Updated Date 11/8/2025 |
52 Weeks Range 1.92 - 21.17 | Updated Date 11/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.79 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -1.02 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.38% | Return on Equity (TTM) -140.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 670442283 | Price to Sales(TTM) - |
Enterprise Value 670442283 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52821689 | Shares Floating 29509383 |
Shares Outstanding 52821689 | Shares Floating 29509383 | ||
Percent Insiders 5.52 | Percent Institutions 79.3 |
Upturn AI SWOT
Kodiak Sciences Inc
Company Overview
History and Background
Kodiak Sciences Inc. was founded in 2006 and focuses on developing novel therapeutics to treat chronic, high-prevalence retinal diseases. It is known for its Antibody Biopolymer Conjugate (ABC) platform.
Core Business Areas
- Retinal Disease Therapeutics: Developing therapies for retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Leadership and Structure
Victor Perlroth is the CEO. The company has a board of directors and operates with a structure typical of a biotechnology company focused on R&D.
Top Products and Market Share
Key Offerings
- Tarcocimab Tedromil (KSI-301): Tarcocimab Tedromil is an investigational anti-VEGF antibody biopolymer conjugate being developed for the treatment of wet AMD, DME, and RVO. There is no market share data for KSI-301 as it is not yet approved. Competitors include Regeneron's Eylea and Roche's Vabysmo.
Market Dynamics
Industry Overview
The retinal disease therapeutics market is large and growing due to the aging population and increasing prevalence of diabetes. It is dominated by anti-VEGF therapies.
Positioning
Kodiak Sciences aims to compete with existing anti-VEGF therapies by offering longer-lasting treatments, potentially reducing the frequency of injections.
Total Addressable Market (TAM)
The global market for retinal disease therapies is expected to reach billions of dollars. Kodiak Sciences aims to capture a significant portion with a longer-lasting treatment.
Upturn SWOT Analysis
Strengths
- ABC platform technology
- Potential for less frequent dosing
- Strong intellectual property portfolio
Weaknesses
- Dependence on a single lead product candidate
- High cash burn rate
- Clinical trial risks and regulatory hurdles
Opportunities
- Expanding indications for KSI-301
- Partnerships with larger pharmaceutical companies
- Developing new therapies using the ABC platform
Threats
- Competition from established anti-VEGF therapies
- Clinical trial failures
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- REGN
- RHHBY
Competitive Landscape
Kodiak Sciences faces strong competition from established players. Its competitive advantage lies in the potential for less frequent dosing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial milestones.
Future Projections: Future growth depends on the successful development and commercialization of KSI-301 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Focus on clinical trials for KSI-301 in wet AMD, DME, and RVO.
Summary
Kodiak Sciences is a clinical-stage biotech company with a promising platform technology, but it faces significant risks and competition. Success hinges on the clinical trial results of KSI-301. The company needs to demonstrate a clear advantage over existing therapies to gain market share and should look for partnership opportunities. The balance sheet and cashflow need to be monitored closely.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 121 | Website https://kodiak.com |
Full time employees 121 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.